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Background/Aims: Although endoscopic ultrasound 
guided fine needle aspiration (EUS-FNA) has been in-
troduced and its use has been increasing in Korea, 
there have not been many reports about its perfor-
mance. The aim of this study was to assess the utili-
ty of EUS-FNA without on-site cytopathologist in esta-
blishing the diagnosis of solid pancreatic and peri-
pancreatic masses from a single institution in Korea. 
Methods: Medical records of 139 patients who under-
went EUS-FNA for pancreatic and peripancreatic solid 
mass in the year 2007, were retrospectively reviewed. 
By comparing cytopathologic diagnosis of FNA with fi-
nal diagnosis, sensitivity, specificity, and accuracy 
were determined, and factors influencing the accuracy 
as well as complications were analyzed. Results: 
One hundred twenty out of 139 cases had final diag-
nosis of malignancy. Sensitivity, specificity, and accu-
racy of EUS-FNA were 82%, 89%, and 83%, re-
spectively, and positive and negative predictive values 
were 100% and 46%, respectively. As for factors in-
fluencing the accuracy of FNA, lesion size was mar-
ginally significant (p-value 0.08) by multivariate analy-
sis.  Conclusions: EUS-FNA performed without on-site 
cytopathologist was found to be accurate and safe, 
and thus EUS-FNA should be a part of the standard 
management algorithm for pancreatic and peripancre-
atic mass. (Gut and Liver 2009;3:116-121)
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INTRODUCTION
  Pancreas cancer is a malignancy that has a very poor 
prognosis. Although its diagnosis can be suspected on 
noninvasive imaging modalities such as MDCT, MRI and 
PET, tissue diagnosis still remains as the confirmatory 
method to diagnose pancreatic cancer.
  Tissue diagnosis was traditionally obtained through op-
eration by exploratory laparatomy and less invasively by 
ultrasound guided transcutaneous fine needle aspiration 
(US-FNA) and CT guided transcutaneous fine needle as-
piration (CT-FNA), but the latter methods require the 
passage of a needle through the skin and layers of various 
organs raising the possibility of needle tract seeding as 
well as other complications.
1
  For these reasons, it has been a common practice to 
undergo operation or chemotherapy based on presumed 
pancreatic cancer without a confirmative tissue diagnosis. 
However, such practice can not be considered ideal as 
this puts the patient at a risk from unnecessary surgery if 
presumed diagnosis of pancreatic cancer turns out to be a 
benign process or other pathologies.
  Endoscopic ultrasound guided fine needle aspiration or 
biopsy (EUS-FNA/B) using linear EUS has several advan-
tages over other modalities for obtaining a tissue diag-
nosis. With high resolution imaging, small lesion not de-
tectable with other modalities can be discovered. Second, 
using a real time doppler imaging, surrounding vascula-
ture can be avoided during tissue acquisition, and third, 
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tained within the boundary of operative resection thus 
negating the risk of tumor spread by the procedure.
2,3
  Recently, EUS-FNA has also been introduced in Korea, 
and a few institutions have been active in its perfor-
mance. A report of its use for evaluation of pancreatic le-
sions was reported in 2005, but the number of the pa-
tients was only 40.
4
  On the other hand, most studies from overseas have 
utilized EUS-FNA in the presence of on-site cytopatho-
logical assistance, but considering the limitation of such 
resources in domestic clinical setting, it is important to 
know the result of EUS-FNA performed without on-site 
cytopathologic evaluation. There have been only a few re-
ports of such nature.
5,6 Therefore, in this study, authors 
aimed to find the operating characteristics of EUS-FNA in 
the evaluation of solid pancreatic and peripancreatic le-
sions from a large number of cases encountered during 
one year at a tertiary referral center without the help of 
on-site cytopathologist and some factors influencing the 
results of EUS-FNA.
MATERIALS AND METHODS
1. Indications for EUS-FNA and patients
  EUS-FNA was performed for evaluation of solid pancre-
atic and peripancreatic lesion excluding pancreatic cystic 
lesions. More specifically, EUS-FNA was first performed 
for tissue diagnosis prior to operation for suspected lo-
calized pancreatic cancer or other pancreatic neoplasms. 
Secondly, it was also performed for more advanced pan-
creatic cancer prior to chemotherapy and also to differ-
entiate between pancreatic cancer and other diseases such 
as focal pancreatitis, metastatic tumor, and lymphoma. 
Thirdly, single or multiple intrabdominal mass lesions 
and adrenal gland lesion not easily approachable from 
other route were also indications for EUS-FNA. A total of 
233 patients underwent EUS-FNA for pancreatic and peri-
pancreatic lesions during the year 2007, and excluding 82 
patients who had pancreatic cystic lesion and 12 patients 
who had inadequate follow up to determine the final na-
t u r e  o f  t h e  l e s i o n  l e f t  1 3 9  p a t i e n t s  ( m a l e  7 5 ,  f e m a l e  6 4 ) 
for the analysis.
  Medical records were reviewed to note the lesion loca-
tion, size, FNA needle type used, result of cytopathologic 
report, final diagnosis, occurrence of complications, clin-
ical features and operative findings.
2. Endoscopic ultrasound guided fine needle aspi-
ration (EUS-FNA)
  EUS was performed in all cases under conscious seda-
tion using midazolam and meperidine. All procedure was 
performed by two experienced endosographists (SSL and 
DWS). Linear EUS (GF-UM 2000, Olympus, Tokyo, Japan 
or GF-UCT 240, Olympus, Tokyo, Japan) was used for 
FNA/B. The type of the needle used in the procedure was 
determined by the operator at will, and they were 22G 
(Echotip-22ECHO 3-22
Ⓡ, Cook Endoscopy, Winston- 
Salem, NC, USA), 19G (Echotip-ECHO 19
Ⓡ, Cook Endos-
copy, Winston-Salem, NC, USA), and TCB (Trucut needle 
Cook Quick-Core, Cook Endoscopy, Winston- Salem, NC, 
USA).
  EUS-FNA was done in following steps. The tip of the 
scope was placed near the lesion of interest, and after 
confirming no intervening vessels were present using real 
time Doppler, the needle was inserted into the lesion. 
After removing the stylet, specimen was obtained by mov-
ing the needle back and forth inside the lesion while ap-
plying negative pressure with 10 cc syringe. Specimen re-
leased by reinsertion of stylet was fixed in formalin for 
cell block or core biopsy. Rest was released and smeared 
on the glass slide using a syringe and cytological analysis 
was performed.
  Trucut biopsy was performed in a similar fashion but 
used a 19 G Trucut needle that has 18 mm specimen tray 
and an automated spring loaded biopsy system to obtain 
a core specimen large enough for histological examina-
tion. All procedures were terminated when the operator 
felt adequate specimen were obtained. No on-site cytopa-
thologic evaluation was available during the procedure. 
When the procedure was finished, the patient was ob-
served in the recovery room for one or two hours to mo-
nitor for symptoms and signs such as abdominal pain, 
nausea, vomiting, gastrointestinal bleeding and perfora-
tion. Next morning, complete blood count, liver function 
test along with serum amylase and lipase were checked.
3. Diagnosis
  Final diagnosis of the patients were confirmed by col-
lective findings of EUS-FNA result, surgical pathology, 
other pathologic result as from US guided biopsy, and by 
clinical and radiological follow up consistent with the di-
agnosis.
4. Data and statistical analysis
  R e s u l t  o f  E U S - F N A / B  w a s  c l a s s i f i e d  a s  m a l i g n a n c y  o r  
benign, and as inadequate when aspirate was poorly cel-
lular or not representative of the target organ. Comparing 
the EUS-FNA result with the final diagnosis as deter-
mined above, sensitivity, specificity, positive predictive 
value, negative predictive value and accuracy of EUS-FNA 
was determined. Inadequate result was considered inaccu-
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Table 1. Baseline Patient and Lesion Characteristics
Mean age (range)
Gender (M：F)
Location of lesions
  Head
  Body/tail
  Multiple
Size of lesion (mean±SD, cm)
No. of passes (mean±SD)
Types of needle
  22G
  19G
  Trucut
  Trucut＋22G
57 (13-85)
1.2：1
55
77
 7
4.05±2.56
2.7 (2.7±0.9)
64
37
30
 8
Table 2. Diagnostic Categories Compared between FNA and 
Final Diagnosis for Malignant Disease
Histology
No. of
positive
FNA cases 
No. of
 final
 Dx cases
Pancreatic adenocarcinoma
Pancreatic neuroendocrine tumor
Solid pseudopapillary tumor
Pancreatic metastasis
Lymphoma
GIST
Malignant rhabdoid tumor
Metastatic LAP*
Adrenal metastasis
Pheochromocytoma
Undifferentiated sarcomatoid ca
71
 2
 7
 5
 3
 4
 1
 2
 1
 1
 1
 88
  2
  8
  6
  3
  6
  1
  2
  1
  1
  1
Total 98 120
FNA, fine needle aspiration.
*Stomach cancer (1), MUO (1).
Table 3. Diagnostic Categories Compared between FNA and 
Final Diagnosis for Benign Disease
Histology
No. of
positive
FNA cases
No. of
final
Dx cases
Focal pancreatitis*
Benign LN enlargement
Tuberculosis
Accessory spleen
Castleman’s diasease
Adrenal adenoma
Organizing fibrous clot
 4 
 3
 6
 1
 1
 1
 1
 5
 4
 6
 1
 1
 1
 1
Total 17 19
FNA, fine needle aspiration.
*Includes one case of autoimmune pancreatitis.
  For the analysis of factors having influence on the re-
sult of EUS-FNA, univariate and multivariate logistic re-
gression analysis was performed using SPSS 12.0 K (SPSS 
Inc., Chicago, IL, USA). For multivariate analysis, back-
ward elimination method was used and p＜0.05 was con-
sidered as statistically significant.
RESULTS
1. Baseline patient and lesion characteristics
  The baseline characteristics of the enrolled patients and 
lesion characteristics are summarized in Table 1. Mean age 
of the 139 patients included in the analysis was 57 years 
(range: 13-85 yr), and male to female ratio was 1.2：1. 
Average number of needle pass per procedure was 2.7 
(2.7±0.9). Sixty four patients were performed with 22G 
fine needle, 30 with 19G Trucut needle, 8 with both 22G 
fine needle and 19G Trucut needle, and 37 patients with 
19G fine needle.
  Average size of the lesion was 4.05±2.56 (range 0.9- 
20.0) cm. Pancreatic lesions consisted of 103 cases and 
peripancreatic lesions 36 cases. When lesions were classi-
fied by location with reference to pancreas into pancreas 
head versus body and tail, 55 could be classified as head 
lesion, while 77 were classified as body/tail lesion, and 7 
lesions were multiple.
  The criteria for determining the final diagnosis was sur-
gical pathology in 48 (35%) patients, other pathological 
result including US-FNA in 13 (9.4%) patients, con-
firmation of disease progression by clinical and radio-
logical follow up in 78 (56%) patients. Average clinical 
and radiologic follow up duration was 144±124 days.
2. Result of EUS-FNA
  Based on the result of FNA, out of 139 total cases, 98 
could be classified as malignant, 24 as benign, and 17 as 
inadequate. Diagnostic categories by FNA result was com-
pared with the final diagnosis as determined by surgical 
or other pathology or clinicoradiological follow up (Tables 
2 and 3). Most common malignancy was pancreatic 
adenocarcinoma. 
  Retrospective review showed that of the 24 cases classi-
fied as benign by FNA result, 7 (29%) turned out to be 
malignant by final diagnosis and were therefore falsely 
negative. CT and EUS findings, however, were suggestive 
of pancreatic cancer in 6 patients, and the other patient 
had raised CA 19-9 level of 411 U/mL and hypermeta-
bolic lesion (SUV 6.1) in the uncinate process of the pan-
creas strongly suggesting the presence of pancreatic can-
cer. These cases were all confirmed as pancreas cancer by 
additional biopsy (n=1), surgery (n=4), and by clinical Hwang CY, et al: EUS-FNA in Diagnosis of Pancreatic and Peripancreatic Lesions   119
Table 4. Utility of EUS-FNA in Establishing the Diagnosis of 
Solid Pancreatic and Peripancreatic Lesions 
Sensitivity
Specificity
Positive predictive value
Negative predictive value
Overall accuracy
 81.7%
 89.5%
 100%
 46.3%
 82.7%
EUS-FNA, endoscopic ultrasound guided fine needle aspira-
tion.
Table 5. Analysis of Factors Having Influence on the Accuracy of EUS-FNA
Variable
Accuracy (%)
 of former
Accuracy (%)
 of latter
p-value in 
univariate 
analysis
p-value in 
multivariate 
analysis*
Location (head vs. body/tail)
Mass size (＜3 cm vs. ＞3)
Organ (pancreas vs. peripancreatic)
No. of passes (1-2 x vs. 3≥) 
Needle types (overall)
  ( 2 2 G  v s .  T C B )
  (22G vs. TCB+22G)
  (22G vs. 19G)
76% (42/55)
71% (32/45)
 82% (84/103)
83% (40/48)
72% (46/64)
 86% (66/77)
 90% (77/86)
 86% (31/36)
 84% (56/67)
 90% (27/30)
100% (8/8)
 92% (34/37)
0.17
0.01
0.54
0.97
0.06
0.06
0.99
0.03
0.08
0.15
0.19
0.99
0.03
EUS-FNA, endoscopic ultrasound guided fine needle aspiration.
*Included variables were location, size, and needle type; n=126.
follow up (n=2). Three (13%) other cases underwent sur-
gery despite benign result on the FNA because neoplastic 
process could not be ruled out, and the result of surgical 
biopsy revealed accessory spleen, organizing fibrin clot, 
and Castleman’s disease, respectively. In the rest of 14 
(58%) cases, additional biopsy was not performed and 
clinical follow up showed benign course in all cases. 
Mean follow up duration for this latter group of patients 
was 9.4 (range: 3.0-17.5) months.
  In 17 cases in which FNA was inadequate, 15 were de-
termined to be malignant and two as benign. For the 15 
cases, seven were diagnosed pathologically (6 surgical, 1 
US-FNA) as pancreas cancer (n=2), solid pseudopapillary 
tumor (n=1), and GIST (n=2), and 8 were diagnosed 
through clinical follow up and by response to chemo-
therapy as pancreas cancer (n=7) and metastatic pancreas 
cancer from the breast cancer (n=1). Of the two benign 
cases, one was diagnosed through surgery as localized 
pancreatic abscess and the other clinically as benign 
lymph node enlargement associated with chronic pancrea-
titis.
  Sensitivity, specificity, accuracy, positive and negative 
predictive value of EUS-FNA were analyzed and are pre-
sented in Table 4.
3. Complications associated with EUS-FNA
  No one had evidence of clinical pancreatitis, but in 11 
cases (8%, 11/139), serum amylase was raised threefold 
or more of normal value the next day. Five of the 11 pa-
tients underwent ERCP on the same day.
4. Factors having influence on the accuracy of 
EUS-FNA
  Factors having influence on the accuracy of EUS-FNA 
was analyzed (Table 5). Lesions smaller or greater than 3 
cm showed accuracy of 71% (32/45) or 90% (77/86), 
respectively. And by the needle type, 22G needle showed 
accuracy of 71% while 19G and TCB needle showed accu-
racy of 92 and 90%, respectively. By univariate analysis, 
lesion size (＜3 cm vs. ≥3 cm) was found as statistically 
significant factor with p-value of 0.01, and needle type 
showed statistical tendency with p-value of 0.06. Multi-
variate analysis with these factors revealed lesion size to 
h a v e  b o r d e r l i n e  s i g n i f i c a n c e  w i t h  p - v a l u e s  0 . 0 8 ,  w h i l e  
needle type showed tendency but without statistical sig-
nificance with p-value of 0.15.
DISCUSSION
  In this study, sensitivity, specificity, and accuracy of 
EUS-FNA in the diagnosis of pancreatic and peripancre-
atic mass lesion was 82%, 89%, and 83%, respectively. 
This is not substantially different from those of previous 
studies published abroad reporting sensitivity of 72-94% 
and specificity of 76-91%.
3,7-10 However, inadequacy rate 
in our study was 12% which is higher than 1.5-4.0% in-
adequacy rate reported by previous studies. This differ-
ence arose because most previous studies unlike ours per-
formed EUS-FNA with the help of on-site cytopathologic 
evaluation. Inadequacy rate in studies in which on-site cy-120   Gut and Liver, Vol. 3, No. 2, June 2009
topathologic evaluation was not available ranged from 
9-20% which is similar to our results.
5,6 In our study, 
negative predictive value was low at 46% but negative 
predictive value has been reported to be low in previous 
studies also. The low negative predictive value may be re-
flecting the fact that pancreas cancer comprised for most 
of lesions. Pancreas cancer when compared with other tu-
mors is associated with more severe inflammation and 
fibrosis in the surrounding tissue, and this may cause 
malignant cells to be not detected even in cytologically 
adequate specimen.
2,8 Therefore, one needs to be very 
cautious when interpreting a negative result of FNA in a 
pancreas lesion, and clinical, radiological, and EUS find-
ings needs to be considered together before concluding 
the lesion is actually benign. If malignancy can not be 
ruled out, additional biopsy and careful clinical follow up 
is thought to be necessary.
  In our study, when analyzed for factors influencing the 
accuracy of EUS-FNA, multivariate analysis showed lesion 
size to have borderline significance with p-value of 0.08. 
Influence of lesion size on the accuracy of EUS-FNA is 
somewhat controversial. Although some studies have 
found no difference in the accuracy of EUS-FNA for le-
sions greater or less than 3 cm in size,
9,11 others includ-
ing this study showed increasing size may be related to 
increased yield of FNA.
12 Further studies will be needed 
to clarify the influence of lesion size on the accuracy of 
EUS-FNA.
  Most studies regarding EUS-FNA have been performed 
with 22G fine needle, and more recently, 19G Trucut nee-
dle have been introduced. In this study, three different 
needle types including 19G fine needle was used, and 
their respective accuracies were compared. The result 
s h o w e d  th a t  n e e d le  t y p e  o th e r t h a n  2 2 G  f in e  n e e d le  w a s 
associated with higher accuracy although significance was 
reduced after multivariate analysis that included other fac-
tors such as lesion size and location. Trucut biopsy has 
the advantage of providing larger tissue specimen and is 
useful in diagnosing diseases where histological analysis 
is required.
13-15 At the same time, however, Trucut biopsy 
is limited by not being able to sample pancreas head le-
sion due to curvature of scope tip when approaching from 
second portion of duodenum. On the other hand, sam-
pling of pancreas head lesion was possible by 19G fine 
needle, and in this study, 10 out of 37 lesions were lo-
cated in the head portion with success rate of 80%. There 
has been fewer report of 19G fine needle than regarding 
Trucut biopsy. In one report, 19G needle was found to be 
useful for diagnosing mediastianal and intrabdominal 
lymph node enlargement including lymphoma by provid-
ing core biopsy in addition to aspiration cytology.
16 
Previous studies have attempted to increase the yield of 
EUS-FNA by incorporating Trucut biopsy with 22G FNA, 
especially in the setting where on-site cytopathology is 
not available.
6,13,17 Although limited in number (n=10), 
our study also showed cases in which Trucut biopsy and 
22G fine needle was performed together, accuracy was 
100%. Although not significant by multivariate analysis, 
result of our study suggests that appropriate use of differ-
ent needles may be one means to improve sample ad-
equacy especially in the clinical setting where on-site cy-
topathological evaluation is not available. We are cur-
rently performing a prospective study with the use of 19G 
needle.
  Although vast majority of malignancy did consist of 
pancreas adenocarcinoma, there were a few cases in 
which final pathologic diagnosis was not pancreas adeno-
carcinoma despite initial imaging seeking differentiation 
with pancreatic cancer. In the present study, there were 5 
cases of metastatic pancreatic tumor, and the primary fo-
cus was breast cancer (n=1), lung cancer (n=2; NSCLC1, 
SCLC1), renal cell cancer (n=1), leiomyosarcoma (n=1), 
and thymic cancer (n=1). In the past, pancreatic mass, 
with its difficult location for biopsy and concern about tu-
mor seeding along the needle tract, was usually operated 
on without tissue confirmation when deemed resectable 
by imaging, and similarly, chemotherapy was not infre-
quently given based solely on imaging diagnosis for non-
resectable disease. However, considering the accuracy and 
the safety of EUS-FNA, pathologic diagnosis of pancreatic 
lesion should be confirmed just like it is done for other 
gastrointestinal neoplasm.
18,19
  In summary, this is the largest Korean study thus far to 
report on the efficacy of EUS-FNA in the evaluation of 
pancreatic and peripancreatic lesions and factors influenc-
ing its success. This study is relevant to the Korean clin-
ical setting where on-site cytopathologist is not available 
most of the time. Despite the absence of on-site cytopa-
thologist, accuracy of EUS-FNA in our study was over 
80%. Such good result along with its excellent safety 
makes us believe EUS-FNA should be considered as part 
of the algorithm for the diagnosis of pancreatic and peri-
pancreatic mass lesions. It can provide a tissue diagnosis 
in most patients, including those in whom the diagnosis 
has proved difficult to establish, and thus guide decisions 
on their subsequent management.
  In addition, our study showed despite the retrospective 
analysis that Trucut biopsy and 19G needle tended to 
have higher diagnostic rate, and this may be further ex-
plored as one of means to improve accuracy in the clin-
ical setting where on-site cytopathologist is not available.Hwang CY, et al: EUS-FNA in Diagnosis of Pancreatic and Peripancreatic Lesions   121
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